Advancing Alzheimer’s Detection

Cogwear Showcases Emerging Neurotech With Policymakers Visiting Penn Medicine’s Perelman Center

With an estimated 7.2 million Americans aged 65 and older living with Alzheimer’s Disease, the need for earlier detection and more objective monitoring has never been greater. Addressing this challenge will depend on stronger collaboration across government, research, and technology sectors.

Cogwear recently had the opportunity to engage with key national leaders, including David McCormick, U.S. Senator for Pennsylvania, NIH Director Dr. Jay Bhattacharya, and Life Sciences Pennsylvania, to discuss the role of emerging neurotechnology in advancing neurological care.

These conversations, held at the Penn Medicine Perelman Center, focused on how innovative platforms like Cogwear’s can help bridge the gap between research and real-world application, supporting earlier detection, more accurate monitoring, and improved outcomes for patients.

Bridging research and real-world impact

Events like this are critical in accelerating the transition from research to real-world application. Cogwear’s work continues to gain momentum through the support of Penn AI and Tech Collaboratory for Healthy Aging and the National Institute of Health, whose collaboration has been instrumental in advancing our Alzheimer’s research.

Our platform is designed to deliver clinical-grade EEG and brain-based insights, enabling earlier detection and more objective monitoring of neurological conditions. Through ongoing studies and pilot programs, we are working to establish a new standard for how cognitive health is measured and understood.

Expanding the frontier: from Alzheimer’s to CTE

While some of our current work is focused on Alzheimer’s disease, the implications extend to other areas of brain health. One of the most promising areas of exploration is Chronic Traumatic Encephalopathy (CTE), a condition that remains largely undetected and difficult to monitor with existing tools.

By applying similar algorithmic approaches, Cogwear aims to measure CTE directly from the brain, which can support earlier intervention, improve safety protocols, and improve long-term outcomes for at-risk populations, including athletes and military personnel.

The importance of continued collaboration

Progress in brain health requires collaboration across the public and private sectors, from policymakers and researchers to clinicians and technology innovators. Conversations like those at the Perelman Center play a vital role in aligning these stakeholders and accelerating meaningful change.

As Cogwear continues to develop and validate its technology, these partnerships will remain essential to bringing scalable, data-driven solutions into real-world settings.

Read more about Cogwear’s approach to Alzheimer’s detection in our latest pilot study.